Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1002/hep.24434/abstract

Viral Hepatitis

Autologous bone marrow mesenchymal stem cell transplantation in liver failure

patients caused by hepatitis B: Short-term and long-term outcomes†‡

Liang Peng1, Dong-ying Xie1, Bing-Liang Lin1, Jing Liu1, Hai-peng Zhu2, Chan

Xie1, Yu-bao Zheng1, Zhi-liang Gao1,*,§

Article first published online: 14 JUL 2011

DOI: 10.1002/hep.24434

Copyright © 2011 American Association for the Study of Liver Diseases

Issue

Hepatology

Volume 54, Issue 3, pages 820–828, 2 September 2011

Abstract

Our study aimed to investigate the short-term efficacy and long-term prognosis

of liver failure patients caused by hepatitis B after a single transplantation

with autologous marrow mesenchymal stem cells (MMSCs). A total of 527 inpatients

with liver failure caused by hepatitis B were recruited and received the same

medical treatments, among whom 53 patients underwent a single transplantation

with autologous MMSCs. A total of 105 patients matched for age, sex, and

biochemical indexes, including alanine aminotransferase (ALT), albumin, total

bilirubin (TBIL), prothrombin time (PT), and Model for End-Stage Liver Disease

(MELD), comprised the control group. A total of 120 mL of bone marrow was

obtained from each patient and then diluted and separated. Then, the MMSC

suspension was slowly transfused into the liver through the proper hepatic

artery. The success rate of transplantation was 100%, without serious side

effects or complications. Levels of ALB, TBIL, and PT and MELD score of patients

in the transplantation group were markedly improved from 2-3 weeks after

transplantation, compared with those in the control group. At 192 weeks of

follow-up, there were no dramatic differences in incidence of hepatocellular

carcinoma (HCC) or mortality between the two groups. Additionally, there were no

significant differences in the incidence of HCC or mortality between patients

with and without cirrhosis in the transplantation group.

Conclusion: Autologous MMSC transplantation is safe for liver failure patients

caused by chronic hepatitis B. Short-term efficacy was favorable, but long-term

outcomes were not markedly improved. In respect to several parameters, this

method is preferable for patients with liver cirrhosis and may have potential

for reducing their incidence of HCC and mortality. (HEPATOLOGY 2011;)